Natera Future Growth

Future criteria checks 4/6

Natera is forecast to grow earnings and revenue by 70.5% and 13.1% per annum respectively. EPS is expected to grow by 69.2% per annum. Return on equity is forecast to be -4.4% in 3 years.

Key information

70.5%

Earnings growth rate

69.2%

EPS growth rate

Biotechs earnings growth	28.5%
Revenue growth rate	13.1%
Future return on equity	-4.4%
Analyst coverage	Good
Last updated	24 Sep 2024

Recent future growth updates

Natera, Inc. (NASDAQ:NTRA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$119

May 12

Recent updates

Natera, Inc.'s (NASDAQ:NTRA) Intrinsic Value Is Potentially 20% Below Its Share Price

Sep 18

Does Natera (NASDAQ:NTRA) Have A Healthy Balance Sheet?

Jul 05

Natera: Overdue For A Breather

Jun 03

Natera, Inc. (NASDAQ:NTRA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$119

May 12

Natera, Inc. (NASDAQ:NTRA) Shares Could Be 46% Below Their Intrinsic Value Estimate

Aug 07

Health Check: How Prudently Does Natera (NASDAQ:NTRA) Use Debt?

May 16

Natera, Inc.'s (NASDAQ:NTRA) Low P/S No Reason For Excitement

Apr 18

Earnings and Revenue Growth Forecasts

NasdaqGS:NTRA - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	1,997	12	177	277	14
12/31/2025	1,708	-137	36	136	17
12/31/2024	1,506	-246	-102	89	17
6/30/2024	1,361	-292	-118	-56	N/A
3/31/2024	1,209	-365	-197	-139	N/A
12/31/2023	1,083	-435	-286	-247	N/A
9/30/2023	989	-499	-311	-270	N/A
6/30/2023	931	-512	-387	-343	N/A
3/31/2023	868	-546	-419	-375	N/A
12/31/2022	820	-548	-479	-432	N/A
9/30/2022	776	-546	-498	-449	N/A
6/30/2022	723	-576	-492	-438	N/A
3/31/2022	667	-546	-453	-398	N/A
12/31/2021	625	-472	-385	-335	N/A
9/30/2021	565	-408	-354	-310	N/A
6/30/2021	505	-315	-280	-252	N/A
3/31/2021	449	-258	-244	-222	N/A
12/31/2020	391	-230	-202	-183	N/A
9/30/2020	362	-189	-139	-124	N/A
6/30/2020	342	-153	-117	-104	N/A
3/31/2020	330	-126	-79	-67	N/A
12/31/2019	302	-125	-68	-63	N/A
9/30/2019	286	-121	-66	-61	N/A
6/30/2019	273	-128	-76	-72	N/A
3/31/2019	262	-129	-107	-103	N/A
12/31/2018	258	-128	-74	-71	N/A
9/30/2018	243	-144	-88	-86	N/A
6/30/2018	233	-142	-97	-94	N/A
3/31/2018	223	-137	N/A	-72	N/A
12/31/2017	210	-138	N/A	-98	N/A
9/30/2017	207	-128	N/A	-99	N/A
6/30/2017	205	-126	N/A	-92	N/A
3/31/2017	205	-121	N/A	-99	N/A
12/31/2016	213	-100	N/A	-74	N/A
9/30/2016	221	-81	N/A	-49	N/A
6/30/2016	212	-72	N/A	-42	N/A
3/31/2016	205	-69	N/A	-35	N/A
12/31/2015	190	-70	N/A	-38	N/A
9/30/2015	187	-46	N/A	-23	N/A
6/30/2015	189	-28	N/A	0	N/A
3/31/2015	179	-6	N/A	13	N/A
12/31/2014	159	-5	N/A	10	N/A
9/30/2014	133	-11	N/A	-4	N/A
3/31/2014	78	-29	N/A	-20	N/A
12/31/2013	55	-37	N/A	-24	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: NTRA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.5%).

Earnings vs Market: NTRA is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: NTRA is expected to become profitable in the next 3 years.

Revenue vs Market: NTRA's revenue (13.1% per year) is forecast to grow faster than the US market (8.7% per year).

High Growth Revenue: NTRA's revenue (13.1% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: NTRA is forecast to be unprofitable in 3 years.

Natera Future Growth

Future criteria checks 4/6

Key information

Recent future growth updates

Consensus estimates of losses per share improve by 20%

Forecast to breakeven in 2026

Forecast to breakeven in 2026

Natera, Inc. (NASDAQ:NTRA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$119

Price target increased by 9.0% to US$113

Natera, Inc. Provides Earnings Guidance for the Year 2024

Recent updates

Co-Founder & Director notifies of intention to sell stock

Natera, Inc.'s (NASDAQ:NTRA) Intrinsic Value Is Potentially 20% Below Its Share Price

Natera, Inc. Announces New Data from the GALAXY Arm of the Ongoing Circulate-Japan Trial at the 2024 Congress of the European Society for Medical Oncology in Barcelona, Spain

Now 23% overvalued after recent price rise

Consensus estimates of losses per share improve by 20%

Forecast to breakeven in 2026

Co-Founder & Executive Chairman exercised options to buy US$22m worth of stock.

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Forecast to breakeven in 2026

Natera, Inc. to Report Q2, 2024 Results on Aug 08, 2024

CEO & Director notifies of intention to sell stock

Does Natera (NASDAQ:NTRA) Have A Healthy Balance Sheet?

Natera, Inc. Announces DECIPHER: A Phase II, Single-Arm Adjuvant Trial in Gastroesophageal Cancer

CEO & Director notifies of intention to sell stock

Natera, Inc. Launches Differentiated New Feature for Prospera Heart Test, Enhancing Detection of Rejection for Transplant Patients

Natera: Overdue For A Breather

New minor risk - Insider selling

Secretary & Chief Legal Officer notifies of intention to sell stock

Natera, Inc. (NASDAQ:NTRA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$119

Price target increased by 9.0% to US$113

Natera, Inc. Provides Earnings Guidance for the Year 2024

First quarter 2024 earnings released: US$0.56 loss per share (vs US$1.23 loss in 1Q 2023)

Natera, Inc. to Report Q1, 2024 Results on May 09, 2024

Natera, Inc., Annual General Meeting, Jun 12, 2024

CEO & Director notifies of intention to sell stock

Now 20% undervalued

Natera, Inc. Announces Publication of Larger Prospective dd-cfDNA Study in Kidney Transplantation

Natera, Inc. Announces New Data from Two Studies Extending the Clinical Validation of Its Prospera Heartd-cfDNA Test for Heart Transplant Recipients

Co-Founder & Director notifies of intention to sell stock

Natera, Inc. and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (Modern) A Randomized, Phase Ii/Iii Adjuvant Trial in Urothelial Cancer

Is There An Opportunity With Natera, Inc.'s (NASDAQ:NTRA) 41% Undervaluation?

Natera: Capitalizing On The Positive Momentum Of Personalized Medicine

Natera, Inc. Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera™? in Stage II Colorectal Cancer

CEO & Director notifies of intention to sell stock

Consensus estimates of losses per share improve by 11%

Is Natera (NASDAQ:NTRA) A Risky Investment?

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Price target increased by 12% to US$86.94

Natera, Inc. Provides Earnings Guidance for the Year 2024

Natera, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Independent Director notifies of intention to sell stock

Chief Financial Officer notifies of intention to sell stock

Natera, Inc. Announces New Study Demonstrates Signatera's Ability to Risk Stratify and Detect Recurrence Early in Resected Stage I-II Lung Cancer

Co-Founder & Director notifies of intention to sell stock

Natera, Inc. Provides Update on Ravgen Trial

Natera, Inc. Provides Revenue Guidance for the Fourth Quarter and Year Ended December 31, 2023

Natera Announces New Study Highlighting the Benefits of Signatera's Unique Method of Quantifying ctDNA

Estimating The Fair Value Of Natera, Inc. (NASDAQ:NTRA)

Natera, Inc. Presents New Signatera™ MRD Data Across Breast Cancer Treatment Settings at SABCS 2023

Natera, Inc. Raises Revenue Guidance for the Full Year 2023

Is Natera (NASDAQ:NTRA) A Risky Investment?

Third quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Natera, Inc. Announces Randomized, Phase III TREAT ctDNA Trial in Early-Stage Breast Cancer

Natera's RenaCARE Study Demonstrates Significant Diagnostic and Clinical Utility of Renasight in Chronic Kidney Disease

Co-Founder & Director notifies of intention to sell stock

Natera, Inc. Announces Updated Data from the Galaxy Arm of the Circulate-Japan Trial

Natera, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Natera, Inc. to Present New Signatera MRD Data At ESMO 2023, Featuring Large, Updated Analysis from CIRCULATE-Japan Study

Natera, Inc. Announces New MRD Publication in Unresectable Stage I-III Lung Cancer Demonstrates Signatera’s Ability to Risk Stratify and Detect Progression Early

Supreme Court Denies CareDx Request for Appeal in Patent Case with Natera

Natera, Inc. Announces Senior Leadership Appointments

Natera, Inc. Announces Expanded I-Spy 2 Collaboration to Evaluate Signatera™? for Breast Cancer Patients in the Neoadjuvant Setting

Natera, Inc. has completed a Follow-on Equity Offering in the amount of $250.25 million.

Natera, Inc. has completed a Follow-on Equity Offering in the amount of $250.25 million.

Co-Founder & Director notifies of intention to sell stock

Natera's Prospera™ Lung Transplant Assessment Test Granted Medicare Coverage

Natera, Inc. (NASDAQ:NTRA) Shares Could Be 46% Below Their Intrinsic Value Estimate

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Natera, Inc. Revises Earnings Guidance for the Year 2023